JP7841846B2 - Ｆｘ活性化を促進する第ｘ因子結合剤 - Google Patents

Ｆｘ活性化を促進する第ｘ因子結合剤

Info

Publication number
JP7841846B2
JP7841846B2 JP2020526504A JP2020526504A JP7841846B2 JP 7841846 B2 JP7841846 B2 JP 7841846B2 JP 2020526504 A JP2020526504 A JP 2020526504A JP 2020526504 A JP2020526504 A JP 2020526504A JP 7841846 B2 JP7841846 B2 JP 7841846B2
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
binding
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020526504A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502984A5 (https=
JP2021502984A (ja
Inventor
ヤコブ・ルンド
カリーナ・トアン
ミッケル・ノルス・ハーンダール
マリー－アンジュ・ビュイセ
エヴリン・デ・タヴェルニエ
ソレン・ステフェンセン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2021502984A publication Critical patent/JP2021502984A/ja
Publication of JP2021502984A5 publication Critical patent/JP2021502984A5/ja
Priority to JP2025269754A priority Critical patent/JP2026040534A/ja
Application granted granted Critical
Publication of JP7841846B2 publication Critical patent/JP7841846B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020526504A 2017-11-15 2018-11-15 Ｆｘ活性化を促進する第ｘ因子結合剤 Active JP7841846B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025269754A JP2026040534A (ja) 2017-11-15 2025-12-19 Ｆｘ活性化を促進する第ｘ因子結合剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17201762.6 2017-11-15
EP17201762 2017-11-15
EP18174634 2018-05-28
EP18174634.8 2018-05-28
PCT/EP2018/081296 WO2019096874A1 (en) 2017-11-15 2018-11-15 Factor x binders enhancing fx activation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025269754A Division JP2026040534A (ja) 2017-11-15 2025-12-19 Ｆｘ活性化を促進する第ｘ因子結合剤

Publications (3)

Publication Number Publication Date
JP2021502984A JP2021502984A (ja) 2021-02-04
JP2021502984A5 JP2021502984A5 (https=) 2021-12-02
JP7841846B2 true JP7841846B2 (ja) 2026-04-07

Family

ID=64426877

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020526504A Active JP7841846B2 (ja) 2017-11-15 2018-11-15 Ｆｘ活性化を促進する第ｘ因子結合剤
JP2025269754A Pending JP2026040534A (ja) 2017-11-15 2025-12-19 Ｆｘ活性化を促進する第ｘ因子結合剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025269754A Pending JP2026040534A (ja) 2017-11-15 2025-12-19 Ｆｘ活性化を促進する第ｘ因子結合剤

Country Status (7)

Country Link
US (2) US11787874B2 (https=)
EP (2) EP4667496A2 (https=)
JP (2) JP7841846B2 (https=)
CN (2) CN111386285B (https=)
ES (1) ES3050257T3 (https=)
MA (1) MA50893A (https=)
WO (1) WO2019096874A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
JP7841846B2 (ja) * 2017-11-15 2026-04-07 ノヴォ ノルディスク アー／エス Ｆｘ活性化を促進する第ｘ因子結合剤
US10815308B2 (en) 2018-12-21 2020-10-27 Kymab Limited FIXaxFX bispecific antibody with common light chain
JP2022548783A (ja) 2019-09-23 2022-11-21 ツイスト バイオサイエンス コーポレーション 単一ドメイン抗体のバリアント核酸ライブラリー
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
EP4314075A4 (en) * 2021-03-24 2025-04-09 Twist Bioscience Corporation VARIANT NUCLEIC ACID BANKS FOR CD3
WO2023111018A1 (en) * 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag Antibodies against coagulation factor x and uses thereof
WO2023225035A2 (en) * 2022-05-16 2023-11-23 Artisan Development Labs, Inc. Compositions and methods for engineering cells
US12098400B2 (en) * 2022-07-08 2024-09-24 Novo Nordisk A/S Highly potent ISVD compounds capable of substituting for FVIII(A)
IL317317A (en) * 2022-07-08 2025-01-01 Novo Nordisk As Highly potent ISVD compounds capable of replacing FVIII(A)
CN115960227A (zh) * 2022-11-08 2023-04-14 河南赛诺特生物技术有限公司 一种抗人msh2的单克隆抗体及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011137000A (ja) 2003-10-10 2011-07-14 Chugai Pharmaceut Co Ltd 機能蛋白質を代替する二種特異性抗体
WO2012067176A1 (ja) 2010-11-17 2012-05-24 中外製薬株式会社 血液凝固第viii因子の機能を代替する機能を有する多重特異性抗原結合分子

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
CA2143126A1 (en) 1993-07-01 1995-01-12 Shamay Tang Process for the preparation of factor x depleted plasma
WO2000007626A1 (en) 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2004041863A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
PT1876236E (pt) 2005-04-08 2014-10-22 Chugai Pharmaceutical Co Ltd Anticorpos para substituição da função do factor de coagulação sanguínea viii
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
EP2915564B1 (en) 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
TWI831106B (zh) 2014-06-20 2024-02-01 日商中外製藥股份有限公司 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
JP6698102B2 (ja) 2015-04-17 2020-05-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 凝固因子と多重特異的抗体を用いた併用療法
US20190185578A1 (en) 2016-07-29 2019-06-20 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
PL3509637T3 (pl) 2016-09-06 2025-03-10 Chugai Seiyaku Kabushiki Kaisha Sposoby zastosowania dwuswoistego przeciwciała, które rozpoznaje czynnik krzepnięcia IX i/lub aktywowany czynnik krzepnięcia IX oraz czynnik krzepnięcia X i/lub aktywowany czynnik krzepnięcia X
TN2019000164A1 (en) 2016-11-23 2020-10-05 Bioverativ Therapeutics Inc Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x
JP7841846B2 (ja) * 2017-11-15 2026-04-07 ノヴォ ノルディスク アー／エス Ｆｘ活性化を促進する第ｘ因子結合剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011137000A (ja) 2003-10-10 2011-07-14 Chugai Pharmaceut Co Ltd 機能蛋白質を代替する二種特異性抗体
WO2012067176A1 (ja) 2010-11-17 2012-05-24 中外製薬株式会社 血液凝固第viii因子の機能を代替する機能を有する多重特異性抗原結合分子

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Kitazawa T. et al.，A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model，Nat Med，2012年，Vol. 18(10)，pp. 1570-1574
Kitazawa T. et al.，Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens，Thromb Haemost，2017年，Vol. 117(7)，pp. 1348-1357
Sampei Z. et al.，Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity，PLoS One，2013年，Vol. 8(2):e57479

Also Published As

Publication number Publication date
MA50893A (fr) 2020-09-23
JP2026040534A (ja) 2026-03-09
US20210054097A1 (en) 2021-02-25
CN118745229A (zh) 2024-10-08
EP3710486A1 (en) 2020-09-23
US20230416404A1 (en) 2023-12-28
CN111386285B (zh) 2024-08-27
ES3050257T3 (en) 2025-12-19
EP3710486B1 (en) 2025-10-08
EP3710486C0 (en) 2025-10-08
US11787874B2 (en) 2023-10-17
EP4667496A2 (en) 2025-12-24
WO2019096874A1 (en) 2019-05-23
JP2021502984A (ja) 2021-02-04
CN111386285A (zh) 2020-07-07

Similar Documents

Publication Publication Date Title
JP7841846B2 (ja) Ｆｘ活性化を促進する第ｘ因子結合剤
CN110248964B (zh) 促凝血抗体
AU2011208719C1 (en) Anticoagulant antidotes
AU2011208719B2 (en) Anticoagulant antidotes
JP7355874B2 (ja) 改良された血液凝固促進抗体
JP2014509856A (ja) ヒト組織因子抗体及びその使用
JP6584397B2 (ja) 凝血促進活性を誘発することができる組織因子経路インヒビターのｎ末端部分を認識する抗体
RU2810748C2 (ru) Усовершенствованные прокоагулянтные антитела
RU2810094C2 (ru) Прокоагулянтные антитела

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211020

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230322

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231102

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231108

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260326

R150 Certificate of patent or registration of utility model

Ref document number: 7841846

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150